ghk-cu austin Peptide in ghk-cu austin Peptide Therapy GHK-CU

Psychiatry 23 , 10511065 (2018)

FOXO4-DRI is a first-in-class senolytic peptide that selectively eliminates senescent "zombie cells" by disrupting the FOXO4-p53 interaction

500 g three times per week for 6 months, 80 or intrathecally (into the cerebrospinal fluid) 2500 g per month for several months

We care about helping patients have increased energy, better sleep, and look their best

A deficiency can lead to fatigue, cognitive decline, and weakened immunity

In this way, we ensure budget neutrality and that the only changes to total payments to ASCs result from increases or decreases in the ASC payment update factor